230 related articles for article (PubMed ID: 31554271)
1. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
3. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
6. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
Du H; Gao L; Luan J; Zhang H; Xiao T
Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
[TBL] [Abstract][Full Text] [Related]
7. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526
[TBL] [Abstract][Full Text] [Related]
8. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.
Moreno MJ; Bosch R; Dieguez-Gonzalez R; Novelli S; Mozos A; Gallardo A; Pavón MÁ; Céspedes MV; Grañena A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
J Pathol; 2015 Feb; 235(3):445-55. PubMed ID: 25231113
[TBL] [Abstract][Full Text] [Related]
10. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
11. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockage of the CXCR4-CXCL12 axis in endometriosis leads to contrasting effects in proliferation, migration, and invasion.
Ruiz A; Ruiz L; Colón-Caraballo M; Torres-Collazo BJ; Monteiro JB; Bayona M; Fazleabas AT; Flores I
Biol Reprod; 2018 Jan; 98(1):4-14. PubMed ID: 29161347
[TBL] [Abstract][Full Text] [Related]
13. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
14. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
[TBL] [Abstract][Full Text] [Related]
15. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
17. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
Recasens-Zorzo C; Cardesa-Salzmann T; Petazzi P; Ros-Blanco L; Esteve-Arenys A; Clot G; Guerrero-Hernández M; Rodríguez V; Soldini D; Valera A; Moros A; Climent F; González-Barca E; Mercadal S; Arenillas L; Calvo X; Mate JL; Gutiérrez-García G; Casanova I; Mangues R; Sanjuan-Pla A; Bueno C; Menéndez P; Martínez A; Colomer D; Tejedor RE; Teixidó J; Campo E; López-Guillermo A; Borrell JI; Colomo L; Pérez-Galán P; Roué G
Haematologica; 2019 Apr; 104(4):778-788. PubMed ID: 29954928
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]